| Dear Amazon Associate, We're writing to tell you about some important changes to the Amazon Services LLC Associates Operating Agreement that may affect your advertising fees. All of these changes will be effective November 1, 2012. * Standard advertising fee rates for Amazon MP3 Products will be 5% and the existing per-unit cap on fees will be removed. * There are additional Excluded Products that are not eligible for advertising fees. For a complete list of the upcoming Operating Agreement changes visit https://affiliate-program.amazon.com/gp/associates/help/operating/compare.We appreciate your continued support and participation in the Amazon Associates Program.
|
This e-mail was sent to ikramullah5555.9211420@blogger.com.
Please note that you must use this e-mail address to access your account in Associates Central or when contacting Associates Customer Service.
To manage your e-mail preferences, update your account settings.
Message Category: Program Rate Changes
© 2012 Amazon.com. All rights reserved. Amazon.com is a registered trademark of Amazon.com, Inc. Amazon.com, 410 Terry Avenue N., Seattle, WA 98109-5210, USA.
The medical application of cobra venom was incorporated into the Materia Medica in the 1800s along with several other snake venoms. In the early 1900s, Calmette (of BCG fame) investigated the use of cobra venom in the treatment of cancer in mice. It was subsequently applied clinically to subjects with cancer where it established a reputation in France for relieving pain. In 1936, Macht, a researcher within the pharmaceutical company, Westcott, Hynson and Dunning, showed that cobra venom, when injected in minute doses, produced analgesic effects that were superior to morphine in activity. In fact, cobra venom was employed when morphine was no longer effective or when patients became addicted to the opiate. Cobra venom proved to be 80% effective in the clinic for the treatment of headache and arthritis pain and it allowed long-term control of chronic pain conditions without addictive problems. A feature of this venom product was its slow onset of analgesic activity however its activity is prolonged. In 1938, acceptance of homeopathic medicine including cobra venom was incorporated into the Food, Drug & Cosmetic Act sponsored by Royal Copeland. In the latter part of the last century cobra venoms were studied for the treatment of severe pain but also rheumatism, trigeminal neuralgia, asthma, ocular therapy, and neuroses. 
